Eleven cases of systemic Pasteurella haemolytica infection in cattle were identified from routine diagnostic laboratory submissions during the falls of 1988, 1989, and 1991. All cases came with a history of recent vaccination with an avirulent live culture P. haemolytica product. Nine of 11 cases involved cattle vaccinated between 2 and 18 days previously with this product. Ten of 11 cases involved 182-227-kg beef calves that were vaccinated between September and November during routine processing for entry into feedlots. The morbidity and mortality was generally low.
Systemic pasteurellosis in the bovine can be caused comparable syndrome in growing feeder cattle has not by either Pasteurella multocida or Pasteurella hae-been described. molytica. The most significant Pasteurella septicemia syndrome on a worldwide basis ticemia of cattle in southern Asi is a.
hemorrhagic sep-Hemorrhagic septicemia causes serious death losses in stressed adult cattle and is caused by P. multocida type 1 or B. 2 Hemorrhagic septicemia is rare in the United States.
In contrast, systemic infection caused by P. haemolytica is not a common syndrome in cattle. Systemic P. haemolytica infection occasionally occurs either in a neonatal calf with multiple problems, suggesting failure of immunoglobulin transfer, or in a growing calf with severe pneumonic pasteurellosis that has spread to other organs in the late stages of the disease. Pasteurella haemolytica septicemia is a well-recognized syndrome in growing feeder lambs caused by P. haemolytica biotype T (serotypes 3, 4, and 10), 3 but a In this paper, 11 cases of systemic P. haemolytica infection in growing cattle are described as a rare sequel to modified live P. haemolytica vaccination.
Materials and methods
The cases presented were received as routine submissions to the South Dakota Animal Disease Research and Diagnostic Laboratory from referring veterinarians in the surrounding service area. The information regarding signalment, morbidity/mortality, and clinical history was taken from the submission forms and in most cases was supplemented by telephone interviews with the referring veterinarians. Necropsy findings were supplied by the referring veterinarian who submitted selected tissues to the diagnostic laboratory or were recorded by the laboratory pathologist when whole animals were submitted.
The type of laboratory work ordered for each case varied, depending on the presenting clinical syndrome and the type --- vine rhinotracheitis (IBR) virus, bovine respiratory syncytial virus (BRSV), and bovine viral diarrhea (BVD) virus. Selected tissues were preserved in 10% neutral buffered formalin, routinely processed, embedded in paraffin, sectioned at 5 µm, and stained with hematoxylin and eosin. In some cases, tissue gram strains were also utilized during histopathologic examination. Pasteurella haemolytica isolates from 2 cases were sent to the National Veterinary Services Laboratory (NVSL) in Ames, Iowa, for serotyping. Three bacterial isolates from 2 different cases were also set to NVSL for restriction enzyme analysis (REA) and were compared with the masterseed of the vaccine involved. a
Results
Summaries of 11 cases of systemic P. haemolytica infection in cattle are presented in Table 1 . Two cases were identified in 1988, 6 cases in 1989, and 3 cases in 199 1. All animals involved were purebred or crossbred beef cattle, except for 1 Holstein heifer. The cases were from the states of South Dakota (7 cases), Iowa (2 cases), and Minnesota (2 cases). The calves ranged in age from 3.5 to 9.5 months. The estimated weights ranged from 182 to 227 kg (400-500 lbs). The sex was not always provided in the record, but both steers and heifers were affected. A total of 9 whole bodies were submitted to the laboratory, and tissues or swabs were submitted from 7 other animals necropsied in the field.
All cases occurred in the fall of the year (September, October, and November) when beef calves in the region are typically weaned and/or processed for feedlots. A variety of different biologicals were given in various combinations to some calves. However, only one bi- ological (an avirulent live culture P. haemolytica vaccine a ) was given to all of the calves involved in these cases. In 4 cases, this was the only biological given to the calves. Calves in these cases were given the vaccine between 2 and 32 days prior to necropsy. In 6 cases, animals were necropsied from 2 to 6 days after vaccination. Four of the remaining 5 animals were necropsied from 14 to 21 days after vaccination. Total number vaccinated, the number showing clinical signs attributed to vaccine associated problems, and the number of dead animals are also listed in Table 1 . The 2 herds with the highest morbidity (case nos. 3 and 4) had a large percentage of animals with swelling and/ or abscessation at the injection site. The remaining affected animals showed clinical signs related to the major lesions found (such as arthritis) or died without clinical signs.
The major pathologic findings are summarized in Table 1 . Microscopic examination revealed major lesions at the cervical injection site of the vaccine in 8 cases, including a combination of hemorrhage, edema, suppurative cellulitis and/or myositis, and abscessa-tion. In 5 cases, there was purulent meningitis. This microscopic lesion was typically severe, with a thick layer of neutrophils expanding the meninges (Fig. 1) . In some cases, bacterial colonies were prominently admixed with the purulent meningeal exudate (Fig. 2) . In 3 cases, polyarthritis was the major pathologic finding. Bronchopneumonia was present in 2 of 16 total animals examined.
Systemic infection was indicated in all cases by the isolation of P. haemolytica from 2 or more organs or distinct anatomical sites in the animal, along with lesions compatible with a bacterial infection. A variety of tissues were cultured according to the presenting clinical complaint. In 6 cases, the vaccination injection site was cultured, and in all 6 cases, P. haemolytica was isolated.
The 2 P. haemolytica isolates sent to the NVSL for serotyping were serotype 1.
Three P. haemolytica isolates were further studied by REA at the NVSL. One isolate each from the vaccine injection site and brain of animal no. 1 (meningitis case) and 1 isolate from the joint of animal no. 2 (ar-thritis case) were compared with P. haemolytica from ably were undergoing major stresses at the time, i.e., the masterseed of the vaccine. All isolates had the same REA pattern (fingerprint) as the masterseed organism. Viral pathogens were identified only in case no. 5. This calf was the only dairy breed animal and had bronchopneumonia with BVD virus identified by fluorescent antibody testing of frozen lung sections. IBR virus was isolated in cell culture from the lung of the same calf. Attempts to identify IBR virus, BVD virus, and BRSV were only conducted in 3 other cases, with negative results.
Discussion
These 11 cases of systemic Pasteurella haemolytica infection in cattle represent a syndrome not previously reported from this service area. All calves that developed systemic infection had been given the same avirulent live Pasteurella haemolytica vaccine product. Typically, cattle were vaccinated with this product while being processed before entry into feedlots, and 2-21 days later the animals were found dead or were euthanized and necropsied because of complications of bacterial infection. Abscessation/cellulitis at the injection site, suppurative meningitis, and suppurative polyarthritis were the major pathologic findings.
At least 12 serotypes of P. haemolytica are recognized in animals. 3 Two isolates from this series of cases were serotyped and identified as serotype 1 strains. Serotype 1 is the most common cause of pneumonic pasteurellosis in cattle and was the serotype used in the avirulent vaccine. The serotype results of this study, although limited, suggested illness in these calves was not due to an outbreak of an unusual P. haemolytica strain.
The exact pathogenesis of systemic infection in this series of cases cannot be accurately determined by observations made from field cases alone; however, a likely pathogenesis is as follows: 1) replication of the avirulent live organisms following vaccination of the cattle (typically by subcutaneous cervical injection); 2) proliferation of the organisms in some animals beyond what is normally expected; 3) dissemination of the organism from the original site by both draining lymphatics and the bloodstream to regional lymph nodes and more distant organs (=systemic infection).
Why systemic infection occurs only rarely in some vaccinated animals is unknown. This avirulent vaccine for cattle is popular in the service area, and many being weaned, processed, and/or shipped to feedlots. Stress can vary greatly among herds because of the variation in age, environmental conditions, and management.
In the field, a problem with this particular vaccine more commonly observed than systemic infection was vaccine-associated abscessation and cellulitis at the injection site (information provided by the Veterinary Biologics Field Office via USDA/APHIS Freedom of Information Office, Hyattsville, MD). Abscesses at the injection site typically respond to antibiotic therapy and/or surgical drainage. The reason for the development of abscesses and cellulitis in some animals following vaccination with this product also is unclear. This vaccine contains avirulent live cultures of P. haemolytica. The lyophilized product is packaged with sterile diluent with which it is mixed immediately prior to use. The dose is 2 cc given subcutaneously to calves >3 months old. Injection of the vaccine deeper into the tissues than recommended is a potential factor in the development of abscesses and septicemia. However, responses to inquiries in these cases indicated that the product had been given as recommended, subcutaneously.
Risks associated with the use of live vaccines have been recently reviewed. 11 Many adverse reactions associated with live vaccine products a accidental contamination with other or to residual virulence of the vaccine organism. 1, [4] [5] [6] [7] 10, 12 Contamination with other infective agents probably re in due either to fective agents was not the problem with common pathogens, other sistently detected in all of the REA test results (on 3 separate thousands of doses have been administered without cases. If residual virulence is responsible for the infecthe development of systemic infection. The systemic tions in these cases, then other cofactors must be in-these than cases. There were no P. haemolytica, concases examined. The isolates) strongly suggested that the organisms that produced the systemic infection were the same as the organisms used to produce the vaccine and tha of the vaccine with other t inadvertent contamination virulent types of P. haemolytica had not occurred. Indirect evidence against a contaminant P. haemolytica organism in the vaccine is also derived from failure to localize the problem to any particular series of the vaccine (information provided by the Veterinary Biologics Field Office via USDA/APHIS Freedom of Information Office, Hyattsville, MD).
The issue of possible residual virulence of the vaccine organism remains open but is the most likely explanation of the systemic infection in this series of infection does not appear to be related to concurrent volved because not all animals vaccinated developed disease problems because no other major health probsystemic infection or abscesses. Adverse reactions are lems were identified in these animals at necropsy, with rare and series of the vaccine involved have been rethe exception of concurrent IBR and BVD virus intested and have passed safety testing procedures (infections in case no. 5. All of the affected animals prob-formation provided by the Veterinary Biologics Field Office via USDA/APHIS Freedom of Information Office, Hyattsville, MD).
Immunosuppression in the present cases by contaminant viruses or field viruses also appears unlikely. Virus identification was attempted in 4 cases and was successful in only 1 case (case no. 5, BVD and IBR viruses identified). That case was the only 1 involving a dairy breed animal and was only 1 of 2 cases in which bronchopneumonia was 1 of the lesions present. The calf in case no. 5 may have been in the incubation phase of the classic bovine respiratory disease complex. The role BVD virus may have played in immunosuppression cannot be accurately determined in case no. 5, but BVD virus may be capable of producing immunosuppression. 8, 9 Modified live vaccines are intrinsically more hazardous than inactivated products. 3 However, the desire to stimulate high levels of immunity has encouraged their development and has been balanced against the risks. The company that produces the vaccine used on the infected animals in this report has added a warning to the label, indicating that infrequent injection site pain, swelling or abscesses, lethargy, and musculoskeletal stiffness may occur.
